Механизмы химиопрофилактического действия и эффективность препаратов Индигал, Индигалплюс и Инфемин в отношении рака предстательной железы

Механизмы химиопрофилактического действия и эффективность препаратов Индигал, Индигалплюс и Инфемин в отношении рака предстательной железы

Автор: Сивков А.В., Кирпатовский В.И.

Журнал: Экспериментальная и клиническая урология @ecuro

Рубрика: Экспериментальная урология

Статья в выпуске: 1, 2018 года.

Бесплатный доступ

Цель исследования. Обзор литературы, посвященный анализу действия препаратов Индигал, Индигалплюс и Инфемин, а также активных компонентов, входящих в его состав, на канцерогенез предстательной железы и их эффективности в качестве химиопрофилактических средств у больных с интраэпителиальной простатической неоплазией (PIN) разной степени выраженности, на фоне доброкачественной гиперплазии предстательной железы (ДГПЖ). Объект исследования. Научные публикации из баз данных PubMed, Web of Science, Scopus по экспериментальным и клиническим исследованиям механизма действия активных компонентов изучаемых препаратов: индол-3-карбинол (И3К), его метаболита 3,3'-дииндолилметана (ДИМ), эпигаллокатехин-3-галлата (ЭГКГ), а также экстракта пальмы Serenoa repens. Результаты. Показано, что компоненты препаратов Индигал, Индигалплюс и Инфемин участвуют в регуляции клеточной пролиферации и оказывают выраженное противовоспалительное действие, что, возможно, способствует обратному развитию ПИН при ДГПЖ и торможению пролиферации раковых клеток. Анализируются клеточные механизмы химиопрофилактического действия препаратов и их клиническую эффективность. Заключение. Использование нутрицевтиков для противовоспалительной и противоопухолевой терапии является перспективным направлением современных исследований. Совместное использование разных нутрицевтиков (как в исследуемых препаратах) оказывает более выраженный эффект, чем действие отдельных компонентов. Целесообразно проведение дальнейших исследований противоопухолевой эффективности этих препаратов.

Еще

Индигал, индигалплюс, инфемин, простатическая интраэпителиальная неоплазия (пин), рак предстательной железы, химиопрофилактика рака предстательной железы, индол-3-карбинол, 3 ''-дииндолилметан, дим, эпигаллокатехин-3-галлат, экстракт serenoa repens

Еще

Короткий адрес: https://sciup.org/142213111

IDR: 142213111

Список литературы Механизмы химиопрофилактического действия и эффективность препаратов Индигал, Индигалплюс и Инфемин в отношении рака предстательной железы

  • Аксель Е.М., Давыдов М.И. Заболеваемость злокачественными новообразованиями населения России и стран СНГ в 2008 г. Вестник РОНЦ им. Н.Н. Блохина 2011;22(3, приложение 1):54-92.
  • Злокачественные новообразования в России в 2013 году (заболеваемость и смертность) . М., 2015. 250 с.
  • Аполихин О.И., Сивков А.В., Катибов М.И., Рощин Д.А., Шадеркин И.А., Корякин А.В. Скриннинг рака предстательной железы: оценка с позиций клинико-экономической эффективности. Экспериментальная и клиническая урология 2015;(2):20-24.
  • Каприн А.Д., Аполихин О.И., Сивков А.В., Солнцева Т.В., Комарова В.А. Анализ уронефрологической заболеваемости и смертности в Российской Федерации за период 2002-2014 гг. по данным официальной статистики. Экспериментальная и клиническая урология 2016;(3):4-13.
  • Костин А.А., Асратов А.Т., Кульченко Н.Г., Толкачев А.О. Прогнозирование развития рака предстательной железы с помощью общих моделей дискриминантного анализа. Вестник Российского университета дружбы народов. Серия: Медицина 2015;(3):67-74.
  • Аполихин О.И., Сивков А.В., Кудрявцев Ю.В., Киселев В.И., Ощепков В.Н., Кешишев Н.Г., и др. Применение индол-3-карбинола и эпигаллокатехин-3-галлата при про-статической интраэпителиальной неоплазии для профилактики рака предстательной железы. Эффективная фармакотерапия в урологии2009;(3):2-6.
  • Siegel RL, Miller KD, Jemal A. Cancerstatistics, 2015. CA Cancer J Clrn2015;65(1): 5-29 DOI: 10.3322/caac.21254
  • Schmidt LJ, Tindall DJ. Androgen receptor: past, present and future. Curr Drug Targets 2013;14(4): 401-407.
  • Sharifi N.Minireview: androgen metabolism in castration-resistant prostate cancer. MolEndocrinol 2013;27(5):708-714 DOI: 10.1210/me.2013-1007
  • Chung PH, Gayed BA, Thoreson GR, Raj GV. Emerging drugs for prostate cancer. Expert OpinE-merg Drugs 2013;18(4):533-550 DOI: 10.1517/14728214.2013.864635
  • Dhingra R, Sharma T, Singh S, Sharma S, Tomar P, Malhotra M, et al. Enzalutamide: a novel anti-androgen with prolonged survival rate in CRPC patients. Mini Rev Med Chem 2013;13(10):1475-1486.
  • Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM.Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 2013;73(2):483-489 DOI: 10.1158/0008-5472.CAN-12-3630
  • Antonarakis ES, Lu C, Wang H, Brandon Luber B, Nakazawa M, et al. AR-V7 and resistance to enzalutamide and abirateronein prostate cancer. N Engl J Med 2014;371:1028-1038.
  • Li Y, Kong D,Wang Z, Sarkar FH. Regulation of microRNAs by Natural Agents: An Emerging Field in Chemoprevention and Chemotherapy Research. Pharm Res 2010;27(6):1027-1041 DOI: 10.1007/s11095-010-0105-y
  • Sarkar FH, Li Y, Wang Z, Kong D. Novel targets for prostate cancer chemoprevention. EndocrRelat Cancer 2010;17(3):R195-R212 DOI: 10.1677/ERC-10-0074
  • Kiselev V, Vasilyeva I. A pharmaceutical composition for peroral administration of diindolylmethane. 2011. WO2011034465 A1. URL: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2011034465
  • Cimino S, Sortino G, Favilla V, Castelli T, Madonia M, Sansalone S, et al. Polyphenols: key issues involved in chemoprevention of prostate cancer. Oxid Med Cell Longev 2012;2012:632959 DOI: 10.1155/2012/632959
  • Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol 2011;82(12):1807-21 DOI: 10.1016/j.bcp.2011.07.093
  • Li Y, Wang Z, Kong D, Murthy S, Dou QP, Sheng S, et al. Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. J BiolChem 2007; 282(29): 21542-21550 DOI: 10.1074/jbc.M701978200
  • Li Y, Ahmad A, Kong D, Bao B, Sarkar FH. Recent progress on nutraceutical re-search in prostate cancer. Cancer Metastasis Rev 2014;33(2-3):629-40 DOI: 10.1007/s10555-013-9478-9
  • Rochette-Egly C. Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cellular Signalling 2003;15(4):355-366.
  • Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001;20(3):4188-4197 DOI: 10.1038/sj.onc.1204535
  • Li Y, Sarkar F.H. Role of BioResponse 3,3' -Diindolylmethane in the Treatment of Human Prostate Cancer: Clinical Experience. Med PrincPract 2015 DOI: 10.1159/000439307
  • Hussain T, Gupta S, Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 2003;19(2):125-135.
  • Higdon JV, Delage B, Williams DE, Dashwood RH.Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res 2007;55(3):224-236 DOI: 10.1016/j.phrs.2007.01.009
  • Bradlow HL. Indole-3-carbinol as a Chemoprotective Agent in Breast and Prostate Cancer. In vivo 2008;22(4):441-446.
  • Garikapaty VP, Ashok BT, Tadi K, Mittelman A, Tiwari RK. 3,3'-Diindolylmethane downregulates prosurvival pathway in hormone independent prostate cancer. Biochem-Biophys Res Commun. 2006;340(2):718-25 DOI: 10.1016/j.bbrc.2005.12.059
  • Zhang WW, Feng Z, Narod SA. Multiple therapeutic and preventive effects of 3,3'-diindolylmethane on cancers including prostate cancer and high grade prostatic intraepithelial ne-plasia. J Biomed Res 2014;28(5):339-48 DOI: 10.7555/JBR.28.20140008
  • Vivar OI, Lin CL, Firestone GL, Bjeldanes LF. 3,3'-Diindolylmethane induces a G(1) arrest in human prostate cancer cells irrespective of androgen receptor and p53 status. BiochemPharmacol. 2009;78(5):469-76 DOI: 10.1016/j.bcp.2009.05.008
  • Bhuiyan MM, Li Y, Banerjee S, Wang Z, Ali S, Sarkar FH. Downregulation of an-drogen receptor by 3,3 ' -diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormonesensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res 2006; 66(20):10064-10072 DOI: 10.1158/0008-5472.CAN-06-2011
  • Li Y, Kong D, Wang Z, Ahmad A, Bao B, Padhye S, et al. Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells. Cancer Prev Res (Phila) 2011;4(9):1495-506 DOI: 10.1158/1940-6207.CAPR-11-0077
  • Kong D, Banerjee S, Huang W, Li Y, Wang Z, Kim HR, Sarkar FH. Mammalian target of rapamycin repression by 3, 3' -diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells. Cancer Research 2008;68(6):1927-1934 DOI: 10.1158/0008-5472.CAN-07-3241
  • Aggarwal BB, Ichikawa H. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle 2005;4(9):1201-1215 DOI: 10.4161/cc.4.9.1993
  • Singh-Gupta V, Banerjee S, Yunker CK, Rakowski JT, Joiner MC, Konski AA, et al. B-DIM impairs radiation-induced survival pathways independently of androgen receptor expression and augments radiation efficacy in prostate cancer. Cancer Lett 2012;318(1):86-92 DOI: 10.1016/j.canlet.2011.12.006
  • Tsai JY, Chou CT, Liu SI, Liang WZ, Kuo CC, Liao WC, et al. Effect of diindol-yl-methane on Ca2+ homeostasis and viability in PC3 human prostate cancer cells. J Recept Signal Transduct Res. 2012;32(5):271-8 DOI: 10.3109/10799893.2012.707212
  • Rahman KM, Banerjee S, Ali S, Ahmad A, Wang Z, Kong D, et al. 3,3'-Diin-dolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. Cancer Res 2009;69(10):4468-75 DOI: 10.1158/0008-5472.CAN-08-4423
  • Chen D, Banerjee S, Cui QC, Kong D, Sarkar FH, Dou QP. Activation of AMP-activated protein kinase by 3,3'-Diindolylmethane (DIM) is associated with human prostate cancer cell death in vitro and in vivo. PLoS One 2012;7(10):e47186 DOI: 10.1371/journal.pone.0047186
  • Cho HJ, Park SY, Kim EJ, Kim JK, Park JH. 3,3-Diindolylmethane inhibits prostate cancer development in the transgenic adenocarcinoma mouse prostate model. MolCarcinog 2011;50(2):100-12 DOI: 10.1002/mc.20698
  • Palomera-Sanchez Z, Watson GW, Wong CP, Beaver LM, Williams DE, Dashwood RH, et al. The phytochemical 3,3'-diindolylmethane decreases expression of AR-controlled DNA damage repair genes through repressive chromatin modifications and is associated with DNA damage in prostate cancer cells. J Nutr-Biochem2017;47:113-119 DOI: 10.1016/j.jnutbio.2017.05.005
  • Beaver LM, Yu TW, Sokolowski EI, Williams DE, Dashwood RH, Ho E. 3,3'-Diin-dolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells. ToxicolApplPharmacol 2012;263(3):345-51 DOI: 10.1016/j.taap.2012.07.007
  • Kiselev VI, Drukh VM, Muyzhnek EL, Kuznetsov N, Pchelintseva OI, Paltsev MA. Preclinical antitumor activity of the diindolylmethane formulation in xenograft mouse model of prostate cancer. ExpOncol2014. 36;(2):90-93
  • Fares F, Azzam N, Appel B, Fares B, Stein A. The potential efficacy of 3,3'-diindolyl-methane in prevention of prostate cancer development. Eur J Cancer Prev 2010;19(3):199-203 DOI: 10.1097/CEJ.0b013e328333ft>ce
  • Hwang C, Sethi S, Heilbrun LK, Gupta NS, Chitale DA, Sakr WA, et al. Anti-androgenic activity of absorption-enhanced 3, 3'-diindolylmethane in prostatectomy patients. Am J Transl Res 2016;8(1):166-76.
  • Ahmad A, Kong D, Sarkar SH, Wang Z, Banerjee S, Sarkar FH. Inactivation of uPA and its receptor uPAR by 3,3'-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration. J Cell Biochem 2009;107(3):516-27 DOI: 10.1002/jcb.22152
  • Nayak D, Amin H, Rah B, Ur Rasool R, Sharma D, Gupta AP,Kushwaha M, Mukherjee D, Goswami A. A therapeutically relevant, 3,3'-diindolylmethane derivative NGD16 attenuates angiogenesis by targeting glucose regulated protein, 78kDa (GRP78). ChemBiol Interact 2015;232:58-67 DOI: 10.1016/j.cbi.2015.03.008
  • Howells LM, Moiseeva EP, Neal CP, Foreman BE, Andreadi CK,Sun YY, et al. Predicting thephysiological relevance of in vitro cancer preventive activities of phytochemicals. Acta Pharmacol Sin 2007;28(9):1274-1304.doi: 10.1111/j. 1745-7254.2007.00690.x10.1111/j. 1745-7254.2007.00690.x
  • Anderton MJ, Manson MM, Verschoyle RD, Gescher A, Lamb JH, Farmer PB, et al. Pharmacokinetics and tissue disposition of indole-3-carbinol and its acid condensation products after oral administration to mice. Clin Cancer Res2004;10(15):5233-41 DOI: 10.1158/1078-0432.CCR-04-0163
  • Wang TT, Schoene NW, Milner JA, Kim YS. Broccoli-derived phytochemicals in-dole-3-carbinol and 3,3'-diindolylmethane exerts concentration-dependent pleiotropic effects on prostate cancer cells: comparison with other cancer preventive phytochemicals. MolCarcinog 2012;51(3):244-56 DOI: 10.1002/mc.20774
  • Li Y, Sarkar FH. Role of BioResponse 3,3'-Diindolylmethane in the Treatment of Human Prostate Cancer: Clinical Experience. Med PrincPract 2016;25 (Suppl 2): 11-7 DOI: 10.1159/000439307
  • Cho HJ, Park SY, Kim EJ, Kim JK, Park JH. 3,3'-Diindolylmethane inhibits prostate cancer development in the transgenic adenocarcinoma mouse prostate model. MolCarcinog 2011;50(2):100-12 DOI: 10.1002/mc.20698
  • Gee JR, Saltzstein DR, Messing E, Kim K, Kolesar J, Huang W, et al. Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane(BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy.Eur J Cancer Prev. 2016;25(4):312-20 DOI: 10.1097/CEJ.0000000000000189
  • Heath EI, Heilbrun LK, Li J, Vaishampayan U, Harper F, Pemberton P, et al. A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'-Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer. Am J Transl Res 2010;2(4):402-11.
  • Goldberg AA, Draz H, Montes-Grajales D, Olivero-Verbél J,Safe SH, Sanderson JT.3,3'-Diindolylmethane (DIM) and its ringsubstituted halogenated analogs(ring-DIMs) induce differential mechanisms of survival and death inandrogen-dependent and -independent prostate cancer cells. GenesCancer 2015;6(5-6):265-280.
  • Gupta S, Mukhtar H. Green tea and prostate cancer. UrolClin North Am 2002;29(1):49-57.
  • Jian L, Lee AH, Binns CW. Tea and lycopene protect against prostate cancer. Asia Pac J ClinNutrAsia Pac J ClinNutr 2007;16(Suppl 1):453-7.
  • Kurahashi N, Sasazuki S, Iwasaki M, Inoue M, Tsugane S. Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol 2008;167(1):71-7 DOI: 10.1093/aje/kwm249
  • McCracken M, Olsen M, Chen MS Jr, Jemal A, Thun M, Cokkinides V, et al. Can-cer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin 2007;57(4):190-205.
  • Butt MS, Ahmad RS, Sultan MT, Qayyum MM, Naz A. Green tea and anticancer perspectives: updates from last decade. Crit Rev Food SciNutr 2015;55(6):792-805 DOI: 10.1080/10408398.2012.680205
  • Hu G, Zhang L, Rong Y, Ni X, Sun Y. Downstream carcinogenesis signaling pathways by green tea polyphenols: a translational perspective of chemoprevention and treatment for cancers. Curr DrugMetab 2014;15(1):14-22.
  • Lecumberri E, Dupertuis YM, Miralbell R, Pichard C. Green tea polyphenol epigal-locatechin-3-gallate (EGCG) as adjuvant in cancer therapy. Clin Nutr 2013;32(6):894-903 DOI: 10.1016/j.clnu.2013.03.008
  • Vayalil PK, Katiyar SK. Treatment of epigallocatechin-3-gallate inhibits matrix met-alloproteinases-2 and -9 via inhibition of activation of mitogen-activated protein kinases, c-jun and NF-kappaB in human Prostate carcinoma DU-145 cells. Prostate 2004;59(1):33-42 DOI: 10.1002/pros.10352
  • Hagen RM, Chedea VS, Mintoff CP, Bowler E, Morse HR, Ladomery MR. Epigal-locatechin-3-gallate promotes apoptosis and expression of the caspase 9a splice variant in PC3 prostate cancer cells. Int J Oncol 2013;43(1):194-200 DOI: 10.3892/ijo.2013.1920
  • Lee YH, Kwak J, Choi HK, Choi KC, Kim S, Lee J, et al. EGCG suppresses pros-tate cancer cell growth modulating acetylation of androgen receptor by anti-histone acetyl-transfer-ase activity. Int J Mol Med 2012;30(1):69-74 DOI: 10.3892/ijmm.2012.966
  • Khan N, Mukhtar H. Multitargeted therapy of cancer by green tea polyphenols. Cancer Lett2008;269(2):269-80 DOI: 10.1016/j.canlet.2008.04.014
  • Qin J, Xie LP, Zheng XY, Wang YB, Bai Y, Shen HF, et al. A component of green tea, (-)-epigallocatechin-3-gallate, promotes apoptosis in T24 human bladder cancer cells via modulation of the PI3K/Akt pathway and Bcl-2 family proteins. BiochemBiophys Res Commun2007;354(4):852-857 DOI: 10.1016/j.bbrc.2007.01.003
  • Chung LY, Cheung TC, Kong SK, Fung KP, Choy YM, Chan ZY, Kwok TT. In-duction of apoptosis by green tea catechins in human prostate cancer DU145 cells. Life Sci 2001;68(10):1207-1214.
  • Henning SM, Wang P, Carpenter CL, Heber D. Epigenetic effects of green tea polyphenols in cancer. Epigenomics 2013;5(6):729-41 DOI: 10.2217/epi.13.57
  • Fang M, Chen D, Yang CS. Dietary polyphenols may affect DNA methylation. J Nutr 2007;137(1 Suppl):223S-228S.
  • Pandey M, Gupta S. Green tea polyphenols inhibit promoter hypermethylation through downregulation of DNMT expression in prostate cancer LNCaP cells. Late Breaking Ab-stract-LB212. AACR Annual Meeting, Apr 14-18, 2007; Los Angeles. ProcAmerAssoc Cancer Res 2007;98:53.
  • Slusarz A, Shenouda NS, Sakla MS, Drenkhahn SK, Narula AS, MacDonald RS, et al. Common botanical compounds inhibit the Hedgehog signaling pathway in prostate cancer. Cancer Res 2010;70(8):3382-90 DOI: 10.1158/0008-5472.CAN-09-3012
  • Mukherjee S, Siddiqui MA, Dayal S, Ayoub YZ,Malathi K. Epigallocatechin-3-gallate suppresses proinflammatory cytokines and chemokines induced by Toll-like receptor 9 ago-nists in prostate cancer cells. JInflamm Res. 2014;7:89-101 DOI: 10.2147/JIR.S61365
  • Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl AcadSci USA 2001;98:10350-10355.doi: 10.1073/pnas.17132609810.1073/pnas.171326098
  • Caporali A, Davalli P, Astancolle S, D'Arca D, Brausi M, Bettuzzi S, et al. The chemopreventive action of catechins in the TRAMP mouse model of prostate Carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis 2004;25(11):2217-2224 DOI: 10.1093/carcin/bgh235
  • Moses MA, Henry EC, Ricke WA, Gasiewicz TA. The heat shock protein 90 inhib-itor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progres-sion model. Cancer Prev Res (Phila). 2015;8(3):249-57 DOI: 10.1158/1940-6207.CAPR-14-0224
  • Adhami VM, Malik A, Zaman N, Sarfaraz S, Siddiqui IA, Syed DN, et al. Com-bined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitoand in vivo. Clin Cancer Res 2007;13(5):1611-1619. CCR-06-2269.CCR-06-2269 DOI: 10.1158/1078-0432
  • Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemopreven-tion of human Prostate Cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006;66(2):1234-1240. doi: 10.1158/0008-5472.CAN-05-114510.1158/0008-5472.CAN-05-1145
  • Brausi M, Rizzi F, Bettuzzi S. Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update.EurUrol 2008;54(2):472-3 DOI: 10.1016/j.eururo.2008.03.100
  • Choan E, Segal R, Jonker D, Malone S, Reaume N, Eapen L, Gallant V. A prospective clinical trial of green tea for hormone refractory Prostate Cancer: an evaluation of the comple-mentary/alternative therapy approach. UrolOncol 2005;23(2):108-113. doi: 10.1016/j.urolonc.2004.10.00810.1016/j.urolonc.2004.10.008.
  • Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, et al. A Phase II Trial of Green Tea in the Treatment of Patients with Androgen Independent Metastatic Prostate Carcinoma. Cancer 2003;97(6):1442-1446 DOI: 10.1002/cncr.11200
  • Eom DW, Lee JH, Kim YJ, Hwang Gs, Kim SN, Kwak JH, et al. Synergistic ef-fect of curcumin on epigallocatechin gallate-induced anticancer action in PC3 prostate cancer cells. BMB Rep 2015;48(8):461 -6.
  • Wang P, Wang B, Chung S, Wu Y, Henning SM, Vadgama JV Increased hemo-preventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells. RSC Adv 2014;4(66):35242-35250 DOI: 10.1039/C4RA06616B
  • Wang P, Henning SM, Heber D, Vadgama JV. Sensitization to docetaxel in prostate cancer cells by green tea and quercetin. J NutrBiochem 2015;26(4):408-15 DOI: 10.1016/j.jnutbio.2014.11.017
  • Henning SM, Aronson W, Niu Y, Conde F, Lee NH, Seeram NP, et al. Teapoly-phenols and theaflavins are present in prostatetissue of humans and miceaftergreen and blacktea-consumption. J Nutr 2006;136(7):1839-1843. Chow HH, Hakim IA, Vining DR, Crowell JA, Ranger-Moore J, Chew WM, et al. Effects of dos-ing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin Cancer Res2005;11(12):4627-4633. 10.1158/1078-0432.CCR-04-2549 DOI: 10.1158/1078-0432.CCR-04-254910
  • Chevalier G, Benard P, Cousse H, Bengone T. Distribution study of radioactivity in rats after oral administration of the lipido/sterolic extract of Serenoa repens (Permixon) supple-mented with -lauric acid, -oleic acid or -beta-sitosterol. Eur J Drug Metab-Pharmacokinet 1997;22:73-83.
  • Habib FK, Ross M, Ho CK, Lyons V, Chapman K. Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression. Int J Cancer 2005;114:190-194. doi:10.1002/ijc.2070110.1002/ijc.20701
  • Di Silverio F, Monti S, Sciarra A, Varasano PA, Martini C, Lanzara S, et al. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia 1998; Prostate 37:77-83.
  • Ravenna L, Di Silverio F, Russo MA, Salvatori L, Morgante E, Morrone S, et al. Effects of the lipidosterolic extract of Serenoa repens (Permixon) on human prostatic cell lines. Prostate 1996;29(4):219-30.
  • Van Coppenolle F, Le Bourhis X, Carpentier F, Delaby G, Cousse H, Raynaud JP, et al. Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat Prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride. Prostate 2000;43(1):49-58
  • Sirab N, Robert G, FasoloV,Descazeaud A, Vacherot F, de la Taille, et al. Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J MolSci 2013; 14:14301-14320 DOI: 10.3390/ijms140714301
  • Кудрявцев Ю.В., Сивков А.В., Разумов С.В., Медведев А.А., Кочетов С.А. Морфологические изменения в ткани предстательной железы больных с доброкачественной гиперплазией предстательной железы при лечении пермиксоном. Урология 2004;(5):10-11
  • Bayne CW, Ross M, Donnelly F, Habib FK. The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) on the prostate. J Urol 2000;164:876-881.
  • Vacherot F, Azzouz M, Gil-Diez-De-Medina S,Colombel M, De La Taille A, Lefrère Belda MA, et al. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia). Prostate 2000;45:259-266.
  • Vela-Navarrete R, Escribano-Burgos M, Farre AL, Garcia-Cardoso J, Manzarbeitia F, Carrasco C. Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activi-ty in prostatic tissue from patients with benign prostatic hyperplasia. J Urol 2005;173:507-510 DOI: 10.1097/01.ju.0000150533.94952.25
  • Vela Navarrete R, Garcia Cardoso JV, Barat A, Manzarbeitia F, Lopez Farre A. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double-blind pilot clinical assay. EurUrol 2003;44:549-55
  • Di Silverio F, Gentile V, De MatteisA, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. EurUrol 2003;43:164-75.
  • Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C, Marberger MJ. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant Prostate. Prostate 2003; 56:171-182 DOI: 10.1002/pros.10238
  • De la TailleA.Therapeutic Approach: The Importance of controlling Prostatic Inflammation. EurUrolSuppl 2013; 12(5): 116-122. doi: http://dx.doi.org/10.1016/j.eursup.2013.08.003
  • Khan N, Mukhtar H. Modulation of signaling pathways in prostate cancer by green tea polyphenols. BiochemPharmacol2013;85(5):667-72 DOI: 10.1016/j.bcp.2012.09.027
  • Connors SK, Chornokur G, Kumar NB. New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer. Nutr Cancer 2012;64(1):4-22 DOI: 10.1080/01635581.2012.630158
  • Jeong WS, Kim IW, Hu R, Kong AN. Modulatory properties of various natural chemopreventive agents on the activation of NF-kappaB signaling pathway. Pharm Res 2004;21(4):661-670.
  • Wong CP, Hsu A, Buchanan A, Palomera-Sanchez Z, Beaver LM,Houseman EA, et al. Effects of sulforaphane and 3,3'-diindolylmethane on genome-wide pro-moter methylation in normal prostate epithelial cells and prostate cancer cells. PLoS One 2014;9(1):e86787 DOI: 10.1371/journal.pone.0086787
  • Киселев В.И., Друх В.М., Муйжнек Е.Л., Кузнецов И.Н., Андрианова ЕА., Барановский П.М. Эффективность применения препарата Инфемин у пациентов с PIN низкой степени с сопутствующей доброкачественной гиперплазией предстательной железы. Экспериментальная и клиническая урология 2015; 3:55-60.
  • Paltsev M, Kiselev V, Muyzhnek E, Drukh V, Muyzhnek E, Kuznetsov I, et al. First results of the double-blind randomized placebo-controlled multicenter clinical trial of DIM-based therapy designed as personalized approach to reverse prostatic intraepithelial neoplasia (PIN). EPMAJ 2016 7:5 DOI: 10.1186/s13167-016-0057-3
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp